Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

4.020 -0.040 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytek Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe
Company to Lead Symposiums at ICCS and ESCCA 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry
The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Why Shares of Cytek Biosciences Dropped This Week
Cytek grew revenue and losses in the first quarter. 
Via The Motley Fool
Where Cytek Biosciences Stands With Analysts
 
Via Benzinga
Cytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services
Sales Organization Enhanced, Platform Organization Created 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Participate in the UBS MedTech, Tools and Genomics Summit
From Cytek Biosciences, Inc.
Via GlobeNewswire
Recap: Cytek Biosciences Q1 Earnings
 
Via Benzinga
Cytek Biosciences Acquires Flow Cytometry & Imaging Business From DiaSorin
 
Via Benzinga
Cytek Biosciences Reports Second Quarter 2023 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Participate in the 44th Annual Goldman Sachs Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023
 
Via Benzinga
Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward
From Cytek Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Unique Fabricating, Inc. (NYSE: UFAB) climbed 205% to $0.55 after gaining around 4% on Tuesday. 
Via Benzinga
Cytek Biosciences Reports First Quarter 2023 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Why Chipotle Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 105% to $0.1730 after the company issued a letter to shareholders. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Introduces New 20-Color AML Panel
Optimized for Cytek Cell Analysis Systems; Single-Tube Panel Accelerates Acute Myeloid Leukemia Research and MRD Detection 
From Cytek Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
From Cytek Biosciences, Inc.
Via GlobeNewswire
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users. 
Via Benzinga
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.